Press information
Nantes, May 10th, 2022

#immunosuppressant #transplantation #LIS1

French biotech company XENOTHERA will present the results of its clinical trial in transplantation at the American Transplant Congress (ATC) in Boston on June 6th, 2022

The results of the first clinical trial of LIS1, XENOTHERA's polyclonal glyco-humanised antibody, induction immunosuppressant for solid organ transplantation, will be presented at the American Transplant Congress (ATC) to be held in Boston (USA) from June 4th to 8th.

XENOTHERA is the sponsor of **the first human clinical study of LIS1, a product from its glyco-humanized antibody platform, indicated for the prevention of acute rejection in transplantation**. This clinical study (FIH phase I/II) took place in Prag (Czech Republic), under the direction of Professor Ondrej Viklicky, from the IKEM institute, one of the major European renal transplantation centers for several decades.
Ten transplanted patients were included in the clinical trial, which is now completed. The development of the product will continue in the coming months with a confirmatory trial to be conducted in several transplant centers in Europe and the US.

The detailed results of the LIS1 clinical trial, in terms of efficacy (pharmacodynamics) and safety (security, pharmacokinetics of the product) will be presented on Monday June 6th, 2022 at the ATC Congress by Professor Viklicky.

Based on a proprietary technology from INSERM and the University of Nantes. LIS1 is one of the innovative immunotherapy approaches developed by XENOTHERA, this polyclonal depleting antibody has the **dual objective of combining the efficacy of classical depleting agents in transplant induction with the safety of other induction treatments such as anti-IL2Rs, which are less effective.**

This treatment is particularly interesting for transplanters who are facing the risk of toxicity of depleting agents conventionally used in induction, generating in particular an increased risk of infection in the first year after transplantation.

LIS1, through its controlled depletion, will be able to provide transplanted patients with an improved **quality of life, while providing the same effectiveness in preventing acute graft rejection**.

Targeting a market beyond $1 billion, the new transplant induction therapy LIS1 is an **intravenous solution administered immediately after transplantation for five consecutive days**.

****

About XENOTHERA:

Founded in 2014, XENOTHERA is a Nantes-based biotech that develops new therapeutic modes in many fields (immunology, oncology, viral infections...). The company develops treatments based on a unique proprietary technology for the production of "glyco-humanised" polyclonal antibodies. Its technological platform is built on a dual expertise in genetics and immunology.
The biotech has a complete portfolio of products, including three products in the clinic: LIS1, an immunosuppressant for solid organ transplantation; XAV-19, an anti-Covid treatment for patients with moderate disease; and XAB05, which will enter the clinic in January 2022 and is intended for the treatment and prevention of multi-drug resistant bacterial infections.
XENOTHERA, a member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of the Pays de la Loire (France). The company has been supported since its creation by private investors, by the Pays de la Loire Region, by BPI France and by the European EIC Fund.

More information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn Twitter

Media Relations:
IZsoGOOD
Ingrid Zémor
+33 6 73 72 99 92
xenothera@izsogood.co